tradingkey.logo

Imfinzi Approved In US For Patients With Early Gastric & Gastroesophageal Cancers

ReutersNov 25, 2025 7:06 PM

- AstraZeneca PLC AZN.L:

  • IMFINZI APPROVED IN THE US AS FIRST AND ONLY PERIOPERATIVE IMMUNOTHERAPY FOR PATIENTS WITH EARLY GASTRIC AND GASTROESOPHAGEAL CANCERS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI